Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project
暂无分享,去创建一个
B Erickson | P E Kinahan | T L Chenevert | Paul Kinahan | B. Erickson | Jayashree Kalpathy-Cramer | Y. Yen | T. Chenevert | P. Korfiatis | K. Schmainda | B. Ross | M. Muzi | C. Quarles | L. Hu | S. Rand | M. Prah | Y. Liu | B. Logan | S. D. Rane | X. Da | B. Hoff | Y. Cao | M. Aryal | T. Dondlinger | L. Bell | Y Cao | K M Schmainda | M A Prah | S D Rand | Y Liu | B Logan | M Muzi | S D Rane | X Da | Y-F Yen | J Kalpathy-Cramer | B Hoff | B Ross | M P Aryal | P Korfiatis | T Dondlinger | L Bell | L Hu | C C Quarles | Y. Cao | Yi-Fen Yen
[1] Zachary S. Kelm,et al. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma , 2015, American Journal of Neuroradiology.
[2] Eun Ja Lee,et al. Perfusion MR Imaging in Gliomas: Comparison with Histologic Tumor Grade , 2001, Korean journal of radiology.
[3] Yuan-Yu Hsu,et al. Is Weisskoff model valid for the correction of contrast agent extravasation with combined T1 and T2* effects in dynamic susceptibility contrast MRI? , 2011, Medical physics.
[4] Michael H Lev,et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.
[5] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[6] D. Aquino,et al. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives , 2017, Journal of immunology research.
[7] Wade M Mueller,et al. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics , 2017, Journal of Neuro-Oncology.
[8] Eric S. Paulson,et al. Spiral Perfusion Imaging With Consecutive Echoes (SPICE™) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility , 2016, Tomography.
[9] Bradley J. Erickson,et al. Dynamic Susceptibility Contrast-MRI Quantification Software Tool: Development and Evaluation , 2016, Tomography.
[10] J. Boxerman,et al. Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. , 2016, Magnetic resonance imaging clinics of North America.
[11] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Hoffmann,et al. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study. , 2011, Journal of neuroradiology. Journal de neuroradiologie.
[13] Leland S. Hu,et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival , 2012, Neuro-oncology.
[14] S. Heiland,et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. , 2015, Neuro-oncology.
[15] Thomas E. Yankeelov,et al. Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO) , 2019, Tomography.
[16] T. Hirai,et al. Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.
[17] Susan M. Chang,et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.
[18] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Junjie Yao,et al. Imaging the aged brain: pertinence and methods. , 2019, Quantitative imaging in medicine and surgery.
[20] Glyn Johnson,et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.
[21] D. Kong,et al. Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.
[22] Andrew D Norden,et al. Response Assessment Challenges in Clinical Trials of Gliomas , 2010, Current oncology reports.
[23] Stephen M. Moore,et al. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.
[24] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[25] Kim Mouridsen,et al. T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[26] W. Mueller,et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.
[27] K. Schmainda,et al. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter‐ and intrapatient comparisons , 2010, Magnetic resonance in medicine.
[28] F. Yamasaki,et al. Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. , 2012, European journal of radiology.
[29] E. Larsson,et al. Calculation of cerebral perfusion parameters using regional arterial input functions identified by factor analysis , 2006, Journal of magnetic resonance imaging : JMRI.
[30] Kamran Paynabar,et al. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients12 , 2015, Translational oncology.
[31] R M Weisskoff,et al. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.
[32] K. Schmainda,et al. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.
[33] M Takahashi,et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.
[34] Brian B. Avants,et al. The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) , 2015, IEEE Transactions on Medical Imaging.
[35] J. Boxerman,et al. Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas , 2017, American Journal of Neuroradiology.
[36] M. Malkin,et al. Delta T1 Method: An Automatic Post-contrast ROI Selection Technique for Brain Tumors , 2010 .
[37] B. D. Ward,et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. , 2004, AJNR. American journal of neuroradiology.
[38] Girolamo Crisi,et al. Differences in Dynamic Susceptibility Contrast MR Perfusion Maps Generated by Different Methods Implemented in Commercial Software , 2014, Journal of computer assisted tomography.
[39] Christopher Joseph Pal,et al. Brain tumor segmentation with Deep Neural Networks , 2015, Medical Image Anal..
[40] J E Heiserman,et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.
[41] Leif Østergaard,et al. Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging , 2002, Magnetic resonance in medicine.
[42] T. Cloughesy,et al. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab , 2015, Journal of Neuro-Oncology.
[43] Glyn Johnson,et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.
[44] J. Vymazal,et al. Response patterns of recurrent glioblastomas treated with tumor-treating fields. , 2014, Seminars in oncology.
[45] B. Rosen,et al. Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.
[46] Natenael B. Semmineh,et al. A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials , 2017, Tomography.
[47] J. Boxerman,et al. Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low–Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors , 2019, American Journal of Neuroradiology.
[48] Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study , 2019, Journal of Neuro-Oncology.
[49] Bradley J Erickson,et al. Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression , 2015, Journal of medical imaging.